2023 European Society of Cardiology guidelines on the management of cardiomyopathies: Statement of endorsement by the NVVC

Judith A. Groeneweg; Bas M. van Dalen; Moniek P. G. J. Cox; Stephane Heymans; Richard L. Braam; Michelle Michels; Folkert W. Asselbergs

doi:10.1007/s12471-025-01955-2

2023 European Society of Cardiology guidelines on the management of cardiomyopathies: Statement of endorsement by the NVVC

Judith A. Groeneweg^*, Bas M. van Dalen, Moniek P. G. J. Cox, Stephane Heymans, Richard L. Braam, Michelle Michels, Folkert W. Asselbergs

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

This article contextualises the 2023 European Society of Cardiology (ESC) guidelines for the management of cardiomyopathies for clinical practice in the Netherlands. The guideline addendum provides additional recommendations for situations where the ESC guidelines may not fully align with Dutch clinical practice. By endorsing the ESC guidelines through this addendum, the Netherlands Society of Cardiology (Nederlandse Vereniging Voor Cardiologie) supports its members in adhering to evidence-based management strategies for cardiomyopathies. As Dutch cardiologists generally adopt the ESC guidelines quickly, this contextualisation is essential for effective application thereof within the Dutch healthcare setting.

Original language	English
Pages (from-to)	148-156
Number of pages	9
Journal	Netherlands Heart Journal
Volume	33
Issue number	5
DOIs	https://doi.org/10.1007/s12471-025-01955-2
Publication status	Published - May 2025

Keywords

Cardiomyopathy
Cardiogenetics
Risk stratification
Management

Access to Document

10.1007/s12471-025-01955-2

Cite this

@article{027cae628af04353a791fe18b0d6f8b3,

title = "2023 European Society of Cardiology guidelines on the management of cardiomyopathies: Statement of endorsement by the NVVC",

abstract = "This article contextualises the 2023 European Society of Cardiology (ESC) guidelines for the management of cardiomyopathies for clinical practice in the Netherlands. The guideline addendum provides additional recommendations for situations where the ESC guidelines may not fully align with Dutch clinical practice. By endorsing the ESC guidelines through this addendum, the Netherlands Society of Cardiology (Nederlandse Vereniging Voor Cardiologie) supports its members in adhering to evidence-based management strategies for cardiomyopathies. As Dutch cardiologists generally adopt the ESC guidelines quickly, this contextualisation is essential for effective application thereof within the Dutch healthcare setting.",

keywords = "Cardiomyopathy, Cardiogenetics, Risk stratification, Management",

author = "Groeneweg, \{Judith A.\} and \{van Dalen\}, \{Bas M.\} and Cox, \{Moniek P. G. J.\} and Stephane Heymans and Braam, \{Richard L.\} and Michelle Michels and Asselbergs, \{Folkert W.\}",

year = "2025",

month = may,

doi = "10.1007/s12471-025-01955-2",

language = "English",

volume = "33",

pages = "148--156",

journal = "Netherlands Heart Journal",

issn = "1568-5888",

publisher = "Bohn Stafleu van Loghum",

number = "5",

}

TY - JOUR

T1 - 2023 European Society of Cardiology guidelines on the management of cardiomyopathies

T2 - Statement of endorsement by the NVVC

AU - Groeneweg, Judith A.

AU - van Dalen, Bas M.

AU - Cox, Moniek P. G. J.

AU - Heymans, Stephane

AU - Braam, Richard L.

AU - Michels, Michelle

AU - Asselbergs, Folkert W.

PY - 2025/5

Y1 - 2025/5

N2 - This article contextualises the 2023 European Society of Cardiology (ESC) guidelines for the management of cardiomyopathies for clinical practice in the Netherlands. The guideline addendum provides additional recommendations for situations where the ESC guidelines may not fully align with Dutch clinical practice. By endorsing the ESC guidelines through this addendum, the Netherlands Society of Cardiology (Nederlandse Vereniging Voor Cardiologie) supports its members in adhering to evidence-based management strategies for cardiomyopathies. As Dutch cardiologists generally adopt the ESC guidelines quickly, this contextualisation is essential for effective application thereof within the Dutch healthcare setting.

AB - This article contextualises the 2023 European Society of Cardiology (ESC) guidelines for the management of cardiomyopathies for clinical practice in the Netherlands. The guideline addendum provides additional recommendations for situations where the ESC guidelines may not fully align with Dutch clinical practice. By endorsing the ESC guidelines through this addendum, the Netherlands Society of Cardiology (Nederlandse Vereniging Voor Cardiologie) supports its members in adhering to evidence-based management strategies for cardiomyopathies. As Dutch cardiologists generally adopt the ESC guidelines quickly, this contextualisation is essential for effective application thereof within the Dutch healthcare setting.

KW - Cardiomyopathy

KW - Cardiogenetics

KW - Risk stratification

KW - Management

U2 - 10.1007/s12471-025-01955-2

DO - 10.1007/s12471-025-01955-2

M3 - Article

SN - 1568-5888

VL - 33

SP - 148

EP - 156

JO - Netherlands Heart Journal

JF - Netherlands Heart Journal

IS - 5

ER -

2023 European Society of Cardiology guidelines on the management of cardiomyopathies: Statement of endorsement by the NVVC

Abstract

Keywords

Access to Document

Fingerprint

Cite this